LABORATORY RESEARCH
Alternative Promoter Usage at the Notch1 Locus Supports Ligand-Independent Signaling in T Cell Development and Leukemogenesis
Loss of the transcription factor Ikaros is correlated with Notch receptor activation in T cell acute lymphoblastic leukemia. However, the mechanism remains unknown. Researchers identified promoters in Notch1 that drove the expression of Notch1 proteins in the absence of a ligand. [Immunity]
Regulation of Hematopoietic Stem Cells by Their Mature Progeny
Here, researchers demonstrate that the megakaryocytosis and increased platelet mass in mice with mutations in the Myb or p300 genes causes reduced circulating thrombopoietin (TPO) concentration and TPO starvation of the stem-cell compartment, which is exacerbated because these cells additionally exhibit impaired responsiveness to TPO. [Proc Natl Acad Sci USA]
Synergistic Induction of PI-PLC(Beta)1 Signaling by Azacitidine and Valproic Acid in High-Risk Myelodysplastic Syndromes
In this study, researchers assessed the efficacy of the combination of azacitidine and valproic acid on inducing phosphoinositide-phospholipase C (beta)1 [PI-PLC(beta)1] expression in high-risk myelodysplastic syndrome patients. [Leukemia]
Revealing the Role of TEL/AML1 for Leukemic Cell Survival by RNAi-Mediated Silencing
Translocation (12;21), the most frequent chromosomal aberration in childhood acute lymphoblastic leukemia, creates TEL/AML1 fusion gene. Resulting hybrid protein was shown to have a role in pre-leukemia establishment. To address its role for leukemic cell survival, researchers applied RNA interference to silence TEL/AML1 in leukemic cells. [Leukemia]
Adipose Tissue as a Dedicated Reservoir of Functional Mast Cell Progenitors
In this study, researchers asked whether mast cells present in mice adipose tissue could derive from hematopoietic stem/progenitor cells identified in the tissue. [Stem Cells]
Dasatinib Plus Nutlin-3 Shows Synergistic Anti-Leukemic Activity in Both p53wild-Type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
The purpose of this study was to analyze the effect of the combination of Dasatinib, a multi-kinase inhibitor, plus Nutlin-3, a non-genotoxic activator of the p53 pathway, in primary B chronic lymphocytic leukemia patient samples and B leukemic cell line models. [Clin Cancer Res]
CLINICAL RESEARCH
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Researchers found a substantial reduction in the hazard of death related to allogeneic hematopoietic-cell transplantation, as well as increased long-term survival, over the past decade. [N Engl J Med]
A Markov Decision Analysis of Allogeneic Hematopoietic Cell Transplantation Versus Chemotherapy in Patients with Acute Myeloid Leukemia in First Remission
The results showed that older patients with a related donor and younger patients with unfavorable cytogenetics benefited the most from allogeneic hematopoietic cell transplantation in first complete remission. [Blood]
Autologous Hematopoietic Stem Cell Transplantation in Chronic Lymphocytic Leukemia: Results of European Intergroup Randomized Trial Comparing Autografting Versus Observation
Researchers present results of a phase III randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first or second line treatment. [Blood]
|
|
INDUSTRY NEWS
CGI Raises More Than $100,000 for The Leukemia and Lymphoma Society
CGI Group Inc, a leading provider of information technology and business process services raised $109,000 for the National Capital Area Chapter of The Leukemia and Lymphoma Society® (LLS) through its participation in the Team In Training® (TNT) program. [CGI Group Inc Press Release]
Helix Therapeutics Handed $2.5 Million in New Funding
Helix Therapeutics LLC, a New Haven, Conn.-based biopharmaceutical company, has landed $2.5 million in new funding from venture firm Canaan Partners and the quasi-public state funding entity Connecticut Innovations. [Mass High Tech]
Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology
Pfizer said that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7. Key highlights include results from a Phase III study, called the BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) study, involving bosutinib for the treatment of newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). [Pfizer Press Release]
|
|
EVENTS (Listed by Date)
52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States
5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States
The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China
Highlights of American Society of Hematology (ASH) Vancouver
January 21-22, 2011
Vancouver, Canada
Highlights of American Society of Hematology (ASH) Washington, D.C.
January 28-29, 2011
Washington, D.C., United States
Highlights of American Society of Hematology (ASH) San Francisco
January 28-29, 2011
San Francisco, United States
Highlights of American Society of Hematology (ASH) New York
February 4-5, 2011
New York, United States
Highlights of American Society of Hematology (ASH) San Diego
February 4-5, 2011
San Diego, United States
BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii
Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States
NEW Cell Culture World Congress 2011 – Optimising Cell Culture Development for Biopharmaceutical, Bioprocessing and Manufacture
February 28-March 2, 2011
Munich, Germany
American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada
NEW PITTCON Conference & Expo 2011
March 13-18, 2011
Atlanta, United States
Keystone Symposia: Hematopoiesis
March 27-April 1, 2011
Big Sky, United States
United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom
American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States
37th Annual Meeting of the European Group for Blood and Marrow Transplantation
April 3-6, 2011
Paris, France
NEW World Stem Cells & Regenerative Medicine Congress 2011
May 9-11, 2011
London, United Kingdom
International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)
Lab Technologist – Tissue Culture (STEMCELL Technologies)
Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit!
Comments or Suggestions? Email info@connexoncreative.com with your feedback.
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
